返回Google圖書搜尋

Biologics for Chronic Rhinosinusitis with Nasal Polyps

其他書名	Real-world Evidence in a Translational Perspective
出版	R. van der Lans, 2024
URL	http://books.google.com.hk/books?id=fozW0AEACAAJ&hl=&source=gbs_api

註釋"The last decade gave rise to therapeutic biologics applied in adults with severe chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP). This dissertation seeks to accommodate some of the most pressing scientific needs upon its 2019 post-trial clinical deployment using real world evidence (RWE), and reports on concurrent original findings from clinical and translational research on this topic. Preceded by a general introduction, chapter 2 to 6 derive from real-world, prospective, observational cohort data gathered in PolyREG, the Dutch registry for CRSwNP-patients treated with biologics. Specifically, they detail evaluation of add-on dupilumab as the primary biologic treatment – the agent firstly registered and hence the most evaluable data gathered for hitherto. The following topics are discussed: cross-sectional evaluation of first-year therapeutic safety and efficacy and adequacy of the EPOS2020 indication-criteria; longitudinal 2-year evaluation of therapeutic safety and efficacy of tapered dupilumab conditional to EPOS2020 and EUFOREA-2023 defined biologic-response and CRS-control; incidence, dynamics and prediction of hypereosinophilia after dupilumab initiation and its clinical relevance; the role of total serum-IgE and blood eosinophils as ancillary Type-2 inflammation markers in the EPOS2020 and EUFOREA-2023 biological-indications; and exploration of response-predictive serum biomarkers for dupilumab. Chapter 7 reports the collaborative evaluation of clinically advanced decision making in the high-complex low-frequency situation of biologic switching from conjoint European registries on biologic treatment of (coexisting) CRS and asthma. Chapter 8 contextualizes the findings of this thesis and recommends on some of the most pressing needs to advance the field of biologic treatment of CRS."--